



## **Sanofi strengthens its French-German partnership on the occasion the *French-German Week for Science and Alumni***

**- Proposal for the creation of a French-German Advanced Translational drug discovery Center**

**- Support of the Paris-Berlin Virchow-Villermé University Centre for Public Health**

**Paris, France - April 15, 2013** - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its involvement in two major Franco-German projects in the field of healthcare, on the occasion of the opening of the "French-German Week for Science and Alumni." At a ceremony held at the Institut de France, in the presence of the French Minister for Higher Education and Research Geneviève Fioraso and the German Federal Minister of Education and Research Johanna Wanka, Sanofi announced the signature of memoranda of understanding towards the creation of the French-German Advanced Translational drug discovery Center (FGATC), and its support to the Paris-Berlin Virchow-Villermé University Center for Public Health.

*"As this year marks the fiftieth anniversary of French-German friendship and as a Group with deep roots in both France and Germany, Sanofi is proud to contribute to the move towards the creation of the French-German Advanced Translational drug discovery Center, which should accelerate biomedical discoveries and transform them into new therapies for the benefit of patients,"* said Dr. Elias Zerhouni, President, Global R&D, Sanofi. *"We are also very pleased to support a world class academic partnership and are convinced that the new Paris-Berlin Virchow-Villermé University Centre for Public Health will drive forward public health knowledge, which is a key issue for all governments."*

The **French-German Advanced Translational drug discovery Center** is a unique project of public-private partnership, in which Sanofi would partner with INSERM, the University of Strasbourg, the Mannheim Medical Faculty of the University of Heidelberg and the German Cancer Research Centre (DKFZ). The objective would be to share resources and experiences across the various entities in order to translate biomedical research into new therapies. The location would be planned on two sites in Strasbourg and Heidelberg/Mannheim.

The **Paris-Berlin Virchow-Villermé University Centre for Public Health** will bring together two prestigious universities: the *Charité - Universitätsmedizin Berlin* and the *Sorbonne Paris Cité*. It will provide innovative academic courses in the field of public health and facilitate exchange programs for researchers and students. Sanofi's contemplated contribution would provide funding of two academic chairs for five years for a total budget of 2 million euros.

### **About Sanofi**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).



### **Forward Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

#### **Contacts:**

##### **Corporate Media Relations**

Laurence Bollack

Tel: +33 (0)1 53 77 46 46

E-mail: [laurence.bollack@sanofi.com](mailto:laurence.bollack@sanofi.com)

##### **Investor Relations**

Sébastien Martel

Tel: +33 (0)1 53 77 45 45

E-mail: [ir@sanofi.com](mailto:ir@sanofi.com)